Glenmark Pharmaceuticals Ltd. | GLENMARK | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
| 10,564 | 12,347 | 9,378 | 11,112 | 11,392 |
Short-term investment |
| 0 | 0 | 0 | 0 | 0 |
Accounts receivables |
| 24,043 | 23,318 | 21,946 | 24,090 | 25,721 |
Inventories |
| 21,391 | 20,306 | 22,521 | 21,356 | 22,768 |
Deferred income taxes |
| 0 | 0 | 0 | 0 | 0 |
Other current assets |
| 12,749 | 13,916 | 13,124 | 11,478 | 13,715 |
Total current assets |
| 68,746 | 69,887 | 66,968 | 68,036 | 73,596 |
Gross property plant... |
| 17,837 | 18,958 | 20,978 | 29,777 | 29,578 |
Accumulated Depriciat... |
| 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
| 17,837 | 18,958 | 20,978 | 29,777 | 29,578 |
Work in Progress |
| 6,296 | 9,933 | 12,344 | 10,906 | 12,178 |
Miscellaneous Investment |
| 157 | 147 | 798 | 902 | 246 |
Deferred income taxes |
| 13,113 | 13,203 | 13,830 | 14,557 | 15,347 |
Intangible assets |
| 10,021 | 12,102 | 16,823 | 21,292 | 22,769 |
Goodwill |
| 479 | 521 | 547 | 529 | 580 |
Other long-term assets |
| 991 | 1,203 | 600 | 849 | 1,742 |
Total non-current assets |
| 48,892 | 56,067 | 65,920 | 78,812 | 82,440 |
Total assets |
| 117,639 | 125,954 | 132,888 | 146,848 | 156,036 |
Short-term debt |
| 1,872 | 2,950 | 3,030 | 4,426 | 5,130 |
Accounts Payable... |
| 19,035 | 18,698 | 22,208 | 21,258 | 22,378 |
Provisions |
| 770 | 4,040 | 4,384 | 5,152 | 5,143 |
Taxes Payable |
| 257 | 284 | 458 | 407 | 501 |
Deferred Revenues |
| 0 | 0 | 0 | 0 | 0 |
Capital Leases |
| 0 | 0 | 0 | 0 | 0 |
Other current liabilities |
| 5,093 | 6,906 | 10,132 | 10,016 | 8,858 |
Total current liabilities |
| 27,027 | 32,879 | 40,211 | 41,260 | 42,010 |
Long-term debt |
| 45,363 | 41,418 | 35,738 | 40,430 | 38,888 |
Investments Liabilities |
| 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
| 0 | 0 | 0 | 164 | 287 |
Provisions |
| 0 | 0 | 0 | 0 | 0 |
Capital Leases |
| 0 | 0 | 0 | 0 | 0 |
Other longterm liabilities |
| 327 | 26 | 891 | 4,293 | 4,207 |
Total non-current liabilities |
| 45,691 | 41,444 | 36,629 | 44,887 | 43,383 |
Total liabilities |
| 72,718 | 74,323 | 76,840 | 86,147 | 85,393 |
Share Capital |
| 282 | 282 | 282 | 282 | 282 |
Share premium |
| 0 | 0 | 0 | 0 | 0 |
Retained earnings |
| 44,643 | 51,353 | 55,770 | 60,423 | 70,364 |
Accumulated other equity |
| 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
| 0 | 0 | 0 | 0 | 0 |
Minority Interest |
| -4 | -4 | -4 | -4 | -4 |
Total Equity |
| 44,921 | 51,631 | 56,048 | 60,701 | 70,643 |
Total Liabilities and Equity |
| 117,639 | 125,954 | 132,888 | 146,848 | 156,036 |
Cash per Share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |